Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045Source: DataRank Database

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma is a research paper published in Gynecologic Oncology (2020). On theSindex it has a DataRank of 0.920. It has been cited 18 times, with 15 citing works in its 1-hop citation network.

N/A

0.920DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access18 citations · 15 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01968213

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (58 grants)OA: hybridTopics (22)IDs (PubMed, PMC)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 48%Citation Network 52%

Base Score Contribution

0.442

From this paper's citation signal

Citation Network Contribution

0.478

From 14 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 15 citers.

Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging
Gynecologic Oncology Reports20212 citations11 referencesContributes 0.100
Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data
American Society of Clinical Oncology Educational Book202345 citations63 referencesContributes 0.061
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment
Cancer Treatment Reviews202032 citations65 referencesContributes 0.054
Major clinical research advances in gynecologic cancer in 2019
Journal of Gynecologic Oncology202018 citations57 referencesContributes 0.052
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
International Journal of Molecular Sciences2022115 citations95 referencesContributes 0.050

Authors (26)

Amit M. Oza ORCID,Domenica Lorusso ORCID,Carol Aghajanian ORCID,Ana Oaknin ORCID,Andrew Dean ORCID

Live enrichment

PubMed:32861537 PMC:PMC8450972

NCI NIH HHS

Grant: P30 CA008748

AbbVie

Ajinomoto

Bristol-Myers Squibb

Merck Sharp & Dohme de España SA

PharmaMar

Sanofi

Tesaro

VentiRx

Amgen SA

Merck

Regeneron Pharmaceuticals

Aprea Therapeutics AB

Inivata

PRA International

Serono

TRACON Pharmaceuticals

Aeterna Zentaris

GamaMabs

Millennium Pharmaceuticals

National Institutes of Health

Pierre Fabre

V-Foundation

inVentiv Health Clinical

Ability Pharmaceuticals

AstraZeneca

Cerulean Pharma

Clovis Oncology

Eisai

Merck/Merck Sharp & Dohme

Merus

Roche/Genentech

EMD Serono

ERGOMED Clinical Research

INC Research

ImmunoGen

Janssen

Stemcentrx

Yale University

Agenus

Amgen

F. Hoffmann-La Roche

Genentech

Judy Reis/Albert Pisani

Ludwig Institute for Cancer Research

Ovarian Cancer Research Fund

AbbVie Deutschland

Advaxis

Array BioPharma

Gateway Foundation

Gynecologic Oncology Group

Iovance Biotherapeutics

Janssen Research and Development

Merck Sharp & Dohme

New Mexico Cancer Care Alliance

Novocure

Pfizer

Syndax

hybridLicense: cc-by-nc-nd

publisherhttp://www.gynecologiconcology-online.net/article/S0090825820311306/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0090825820311306?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0090825820311306?httpAccept=text/plain

repositoryhttp://europepmc.org/pmc/articles/PMC8450972

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8450972

MeSH Terms

HumansOvarian NeoplasmsNeoplasm Recurrence, LocalIndolesPlacebosAge FactorsQuality-Adjusted Life YearsTime FactorsQuality of LifeAdultAgedAged, 80 and overMiddle AgedFemaleMaintenance ChemotherapyResponse Evaluation Criteria in Solid TumorsProgression-Free Survival

Keywords

MaintenanceOvarian cancerElderly patientsParp InhibitorRucaparib